Citalopram is a serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) in adults. It is available as tablets, oral solution and capsules. MedsAcross supplies Citalopram for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
CELEXA is indicated for the treatment of major depressive disorder (MDD) in adults. CELEXA is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder (MDD) in adults.
Source: US FDA prescribing information
The mechanism of action of citalopram is unclear, but is presumed to be related to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Source: US FDA prescribing information
Administer once daily with or without food. Initial dosage is 20 mg once daily, after one week may increase to maximum dosage of 40 mg once daily. Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily. When discontinuing CELEXA, reduce dosage gradually.
Source: US FDA prescribing information
CELEXA is contraindicated in patients: taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome. taking pimozide because of risk of QT prolongation. with known hypersensitivity to citalopram or any of the inactive ingredients in CELEXA. Reactions have included angioedema and anaphylaxis. Concomitant use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of discontinuing a MAOI. Concomitant use of pimozide. Known hypersensitivity to citalopram or any of the inactive ingredients of CELEXA.
Source: US FDA prescribing information
Boxed warning (suicidal thoughts and behaviors): Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short -term studies. Closely m onitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. CELEXA is not approved for use in pediatric patients. QT-Prolongation and Torsade de Pointes: Dose-dependent QTc prolongation, Torsade de pointes, ventricular tachycardia, and sudden death have occurred. Avoid use of CELEXA in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. Monitor electrolytes in patients at high risk for hypokalemia or hypomagnesemia.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the labeling: Hypersensitivity reactions Suicidal thoughts and behaviors in adolescents and young adults QT-prolongation and torsade de pointes Serotonin syndrome Increased risk of bleeding Activation of mania or hypomania Discontinuation syndrome Seizures Angle-closure glaucoma Hyponatremia Sexual Dysfunction Most common adverse reaction (incidence ≥ 5% and twice placebo) is ejaculation disorder (primarily ejaculation delay).
Source: US FDA prescribing information
Table 5 presents clinically important drug interactions with CELEXA. Table 5: Clinically Important Drug Interactions with CELEXA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of SSRIs, including CELEXA, and MAOIs increases the risk of serotonin syndrome. Intervention CELEXA is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue. Pimozide Clinical Impact: Concomitant use of CELEXA with pimozide increases plasma concentrations of pimozide, a drug with a narrow therapeutic index, and may increase the risk of QT prolongation and/or ventricular arrhythmias compared to use of CELEXA alone. Intervention: CELEXA is contraindicated in patients taking pimozide.
Source: US FDA prescribing information
CELEXA tablets should be stored at 20-25°C (68 to 77°F), excursions permitted between 15 and 30°C (59-86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Citalopram, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Citalopram 20 mg tabletOralGeneric name | — | US FDA | Available on request |
| Citalopram 40 mg tabletOralGeneric name | — | US FDA | Available on request |
| Citalopram 10 mg tabletOralGeneric name | — | US FDA | Available on request |
| Citalopram 10 mg/5 mL oral solutionOralGeneric name | — | US FDA | Available on request |
| Citalopram 30 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Celexa 10 mg tabletOral | Allergan | US FDA | Available on request |
| Celexa 20 mg tabletOral | Allergan | US FDA | Available on request |
| Celexa 40 mg tabletOral | Allergan | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 17 July 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Citalopram in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Citalopram and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Citalopram, including Celexa.
Yes. The US FDA first approved Citalopram on 17 July 1998, according to Drugs@FDA.
No listed presentation of Citalopram is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Citalopram is classified under ATC code N06AB04 (Citalopram).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.